ArticleRegenerative engineering and translational medicine2025
Delivery of Nucleic Acids for Vascular Tissue Engineering Applications.
Article in Regenerative engineering and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The biomedical research of nucleic acids as therapeutics and their medical applications has been steadily progressing. Identifying the fundamental regulatory roles of nucleic acids and their potential use in the medical field is of major pursuit in current and future research endeavors. Research into nucleic acids for the treatment of vascular diseases has been an emerging avenue as nucleic acids have the ability to treat a variety of pathologies including atherosclerosis. A large part of the translational research in relation to nucleic acids is the development and optimization of drug delivery technologies that can harness the full potential of these molecules, providing untapped, novel therapeutic agents. Specifically, the use of biomaterial delivery systems, consisting of polymers, lipids, and inorganic materials, allows for the protection of nucleic acid therapeutics to promote targeting to regions of vascular damage. While the relevance of nucleic acid therapeutics has been well documented, their functionality for diseases affecting the peripheral vasculature, and the need for biomaterials systems capable of improving their efficacy, has been lacking. This review aims to provide an overview of the biomaterial technologies tested for nucleic acid delivery, relative to the science of applied vascular tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.